Equities

CellSource Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4880:TYO

CellSource Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)395.00
  • Today's Change-15.00 / -3.66%
  • Shares traded68.90k
  • 1 Year change-53.31%
  • Beta0.8053
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.

  • Revenue in JPY (TTM)3.71bn
  • Net income in JPY10.66m
  • Incorporated2015
  • Employees148.00
  • Location
    CellSource Co Ltd11F, Shibuya Cast, 1-23-21, ShibuyaSHIBUYA-KU 150-0002JapanJPN
  • Phone+81 364555308
  • Fax+81 364555968
  • Websitehttps://www.cellsource.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Delta-Fly Pharma Inc0.00-1.65bn2.70bn13.00--7.20-----162.56-162.560.0030.840.00----0.00-352.25-88.06-490.58-97.02-------1,051.54---4,172.580.00-------20.41---61.24--
Perseus Proteomics Inc121.95m-788.76m3.48bn32.00--3.31--28.54-53.50-53.508.2771.390.06681.8510.223,810,875.00-43.18-38.61-46.14-40.7587.2790.16-646.80-837.3014.76--0.00--19.897.0218.08--95.88--
Muromachi Chemicals Inc7.37bn364.59m4.56bn203.0012.431.698.440.619189.5989.591,819.39658.421.233.815.8436,304,700.006.095.998.6610.3629.8529.904.954.891.7618.370.476926.504.464.73-26.9350.1932.64--
Symbio Pharmaceuticals Ltd1.31bn-4.78bn5.57bn108.00--4.07--4.26-95.49-95.4926.0421.390.2961.373.83---108.11-19.84-140.91-24.1572.4574.71-365.25-26.662.74-44.430.6092---46.69-15.23-24.59---11.15--
Kohjin Bio Co Ltd5.20bn719.61m6.27bn167.008.721.085.711.21140.79140.791,017.951,137.250.59953.695.5331,156,770.008.29--11.44--44.58--13.83--1.61--0.2512--9.14--106.44------
MEDRx Co Ltd121.55m-1.26bn6.71bn22.00--3.12--55.19-25.69-25.692.4036.200.04940.05381.825,525,137.00-51.01-50.16-52.60-53.4699.2697.56-1,033.29-1,068.3630.81-180.530.00--773.288.7113.52---74.64--
Nippon Chemiphar Co Ltd32.52bn545.00m7.46bn855.0011.590.32963.640.2293151.00151.009,009.805,309.460.62331.982.7538,035,090.001.040.67941.440.968626.1928.431.681.041.34--0.478555.165.930.5075263.33-7.5832.850.00
K Pharma Inc0.00-993.23m7.95bn17.00--6.28-----85.59-85.590.00109.000.000.00-----37.53---38.74----------28.29-1,982.810.5424-------17.34------
CellSource Co Ltd3.71bn10.66m8.13bn148.00819.441.3538.912.190.50030.5003186.84303.580.52655.9111.3125,077,400.000.151210.680.161311.8956.2464.880.287214.3711.7916.090.009320.88-14.7814.87-95.52-47.768.90--
COSMO BIO COMPANY, LIMITED10.51bn243.00m8.15bn174.0031.620.824420.430.775542.6442.641,842.531,635.050.8916.524.0260,419,540.002.085.382.416.4134.2036.392.345.955.52--0.00241.037.465.75-40.722.038.6828.99
Solasia Pharma KK326.00m-1.80bn8.35bn23.00--4.48--25.60-8.12-8.121.446.910.13830.54315.6714,173,910.00-76.18-64.46-87.38-80.7973.9359.35-550.92-401.814.27-77.040.0547---48.78-24.75-74.55---73.26--
CellSeed Inc120.30m-1.03bn11.16bn38.00--7.98--92.80-29.71-29.713.4737.830.05621.224.753,165,816.00-48.11-45.50-51.99-49.2952.7257.47-856.11-478.147.05--0.0949--1.65-6.87-1.57--6.39--
Wakamoto Pharmaceutical Co Ltd9.29bn298.60m11.29bn286.0037.660.9315.241.218.608.60267.77348.390.60061.623.0632,493,160.001.93-0.06782.22-0.078147.7048.653.21-0.12462.42--0.0082--0.6595-6.53-40.86--21.87--
Data as of Feb 13 2026. Currency figures normalised to CellSource Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

4.34%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 08 Jan 2026367.20k1.85%
Amova Asset Management Co., Ltd.as of 09 Jan 2026170.90k0.86%
Daiwa Asset Management Co. Ltd.as of 30 Dec 2025164.70k0.83%
Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 202676.00k0.38%
BlackRock Japan Co. Ltd.as of 08 Jan 202622.90k0.12%
Asset Management One Co., Ltd.as of 08 Jan 202619.90k0.10%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 30 Sep 202518.00k0.09%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 08 Jan 20269.60k0.05%
Nissay Asset Management Corp.as of 20 Nov 20246.70k0.03%
Norinchukin Zenkyoren Asset Management Co., Ltd.as of 08 Jan 20264.20k0.02%
More ▼
Data from 30 Sep 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.